Isogenica Overview

  • Founded
  • 2000
  • Status
  • Private
  • Employees
  • 27
  • Latest Deal Type
  • Later Stage VC
  • Investors
  • 3

Isogenica General Information


Developer of versatile small-format antibodies designed to construct biotherapeutics for the treatment of cancer, inflammation and other serious diseases. The company's antibodies can be assembled to create bispecific and multi-specific biotherapeutics or used to achieve targeted drug delivery as components of ADCs, cell and gene therapies including CAR-Ts, enabling medical research centers to provide a powerful discovery engine for single domain biotherapeutics.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • The Mansion House
  • Chesterford Research Park, Little Chesterford
  • Essex CB10 1XL
  • England, United Kingdom
+44 01799 000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Isogenica Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 00.000 Completed Generating Revenue
4. Later Stage VC 30-Jun-2014 00.000 Completed Generating Revenue
3. Later Stage VC 29-Nov-2012 00.000 00.000 000.00 Completed Generating Revenue
2. Grant 08-May-2012 $9.2M $3.96M Completed Generating Revenue
1. Later Stage VC 06-May-2008 $3.96M $3.96M 000.00 Completed Generating Revenue
To view Isogenica’s complete valuation and funding history, request access »

Isogenica Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary .6 0,000,000 00.00 00.00 00.00 00.000
Ordinary .747 0,000,000 00.00 00.00 00.00 00.000
To view Isogenica’s complete cap table history, request access »

Isogenica Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Developer of versatile small-format antibodies designed to construct biotherapeutics for the treatment of cancer, inflam
Drug Discovery
Essex, United Kingdom
27 As of 2021
00000 00000 00.000


elit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, su
0000 000000000
Cambridge, United Kingdom
00 As of 0000
0000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Isogenica Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
000000000 00000000 Angel-Backed Cambridge, United Kingdom 00 00.000 0000000000 00.000
You’re viewing 1 of 1 competitors. Get the full list »

Isogenica Patents

Isogenica Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-2500243-A Identifying members of immobilised peptide libraries comprising protein-dna complexes Withdrawn 15-Mar-2012 00000000000
GB-2515944-A Peptide arrays Pending 15-Mar-2012 00000000000
US-20150057162-A1 Peptide arrays Abandoned 15-Mar-2012 00000000000 0
GB-201204605-D0 Peptide arrays Withdrawn 15-Mar-2012 00000000000
GB-201418188-D0 Peptide arrays Pending 15-Mar-2012 G01N33/6845
To view Isogenica’s complete patent history, request access »

Isogenica Executive Team (8)

Name Title Board Seat Contact Info
Emma Sceats Ph.D Chief Executive Officer & Board Member
William Eldridge Chief Scientific Officer
You’re viewing 2 of 8 executive team members. Get the full list »

Isogenica Board Members (9)

Name Representing Role Since
David Burns Self Board Member 000 0000
Emma Sceats Ph.D Isogenica Chief Executive Officer & Board Member 000 0000
Niclas Eriksson Self Board Member 000 0000
Renny Leach Self Board Member 000 0000
You’re viewing 4 of 9 board members. Get the full list »

Isogenica Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Isogenica Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Innovate UK Government Minority 000 0000 000000 0
European Union Seventh Framework Programme Government 000 0000 000000 0
KC Holding Corporation Minority 000 0000 000000 0
To view Isogenica’s complete investors history, request access »